Trial Profile

A Phase 1, 2-Panel, Fixed-Sequence, Open-Label Single-Center Study to Assess the Effect of Single and Multiple Doses of Darunavir in Combination With Cobicistat or Ritonavir on the Pharmacokinetics of Single Dose Dabigatran Etexilate in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/darunavir (Primary) ; Darunavir (Primary) ; Dabigatran etexilate; Ritonavir
Indications HIV-1 infections
Focus Pharmacokinetics
Sponsors Janssen Research & Development

26 Oct 2022 Results assessing the the effect of single and repeated doses of darunavir, coad-ministered with cobicistat or ritonavir, on the pharmacokinetics ofsingle-dose dabigatran etexilate presented at the 16th International Congress on Drug Therapy and HIV Infection
11 May 2021 Status changed from recruiting to completed.
16 Mar 2021 Planned End Date changed from 31 Mar 2021 to 1 Apr 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com